{"id":93875,"date":"2026-06-29T08:03:09","date_gmt":"2026-06-29T08:03:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/93875\/"},"modified":"2026-06-29T08:03:09","modified_gmt":"2026-06-29T08:03:09","slug":"novartis-swxnovn-forms-antares-cancer-partnership-and-expands-disability-access-efforts-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/93875\/","title":{"rendered":"Novartis (SWX:NOVN) Forms Antares Cancer Partnership And Expands Disability Access Efforts"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide. <\/p>\n

Novartis (SWX:NOVN) announced a new oncology R&D partnership with Antares Therapeutics to pursue small molecule drugs for historically undruggable cancer targets. <\/p>\n

The company is also expanding patient impact initiatives through a collaboration with Becoming rentABLE to improve accessible travel options for people living with spinal muscular atrophy. <\/p>\n

These developments broaden Novartis’ focus across cancer drug discovery and real world quality of life support for patients. <\/p>\n

For investors tracking Novartis, the stock trades at CHF126.28 and has delivered a return of 35.3% over the past year and 63.9% over three years. Over five years, SWX:NOVN has returned 89.6%, with shorter term moves of 6.7% over the past week and 5.6% over the past month, and a year to date return of 16.4%. <\/p>\n

Viewed together, the Antares Therapeutics collaboration and accessibility partnership indicate that Novartis is committing capital and attention to both oncology research and patient support ecosystems. Investors watching SWX:NOVN may want to monitor execution progress on the cancer pipeline work and how the broader patient focused programs evolve over time. <\/p>\n

Stay updated on the most important news stories for Novartis<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novartis. <\/p>\n

\"SWX:NOVN<\/a> SWX:NOVN Earnings & Revenue Growth as at Jun 2026 <\/p>\n

We’ve flagged 1 risk for Novartis. See which could impact your investment.<\/a> <\/p>\n

Quick Assessment <\/p>\n

\u2696\ufe0f Price vs Analyst Target: Novartis at CHF126.28 is trading about 1% above the CHF125.03 analyst price target, which is close to consensus. <\/p>\n

\u2705 Simply Wall St Valuation: The stock is flagged as undervalued, trading 59.3% below an estimated fair value. <\/p>\n

\u2705 Recent Momentum: A 5.6% return over the last 30 days shows investors have recently rewarded Novartis. <\/p>\n

There’s only one way to know the right time to buy, sell or hold Novartis. Head to Simply Wall St’s company report for the latest analysis of Novartis’s Fair Value<\/a>. <\/p>\n

Key Considerations <\/p>\n

\ud83d\udcca The oncology R&D deal with Antares and accessibility initiative together point to Novartis leaning into both high impact cancer research and patient quality of life. <\/p>\n

\ud83d\udcca Watch for clinical milestones from the small molecule cancer pipeline and any quantified spend or returns from these partnerships in future reports. <\/p>\n

\u26a0\ufe0f With one flagged risk related to a high level of debt, investors may want to track leverage and funding needs as R&D commitments expand. <\/p>\n

Dig Deeper <\/p>\n

For the full picture including more risks and rewards, check out the complete Novartis analysis<\/a>. Alternatively, you can check out the community page for Novartis<\/a> to see how other investors believe this latest news will impact the company’s narrative. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVN.SW<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":93876,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[45941,45942,206,265,3378],"class_list":["post-93875","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-antares","tag-cancer-drug-discovery","tag-novartis","tag-oncology","tag-simply-wall-st"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116832357866522132","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/93875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=93875"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/93875\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/93876"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=93875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=93875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=93875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}